Financial Avengers Inc. Purchases 874 Shares of Johnson & Johnson $JNJ

Financial Avengers Inc. lifted its position in Johnson & Johnson (NYSE:JNJ) by 1.8% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 49,345 shares of the company’s stock after buying an additional 874 shares during the period. Johnson & Johnson comprises 3.5% of Financial Avengers Inc.’s holdings, making the stock its 10th largest position. Financial Avengers Inc.’s holdings in Johnson & Johnson were worth $7,537,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Clark Asset Management LLC raised its position in Johnson & Johnson by 51.6% in the 2nd quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock valued at $1,357,000 after buying an additional 3,025 shares during the last quarter. Apexium Financial LP lifted its position in shares of Johnson & Johnson by 10.7% in the first quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock worth $3,978,000 after purchasing an additional 2,310 shares in the last quarter. Avanza Fonder AB increased its stake in Johnson & Johnson by 2.9% in the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock valued at $35,842,000 after buying an additional 6,566 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. lifted its position in Johnson & Johnson by 7.0% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company’s stock worth $12,164,000 after buying an additional 4,816 shares in the last quarter. Finally, Klingman & Associates LLC grew its holdings in shares of Johnson & Johnson by 13.4% in the 1st quarter. Klingman & Associates LLC now owns 16,984 shares of the company’s stock valued at $2,817,000 after acquiring an additional 2,005 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Raymond James Financial increased their price target on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research report on Wednesday, October 15th. Bank of America raised their target price on shares of Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a research note on Wednesday, October 15th. Johnson Rice set a $190.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a report on Wednesday, October 22nd. Loop Capital set a $190.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 22nd. Finally, UBS Group boosted their price objective on shares of Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a research note on Tuesday, October 14th. Four equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $201.05.

Johnson & Johnson Price Performance

Shares of JNJ opened at $207.75 on Thursday. The company’s 50-day moving average is $190.05 and its 200-day moving average is $172.75. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The firm has a market capitalization of $500.53 billion, a PE ratio of 20.05, a PEG ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $207.81.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion for the quarter. Equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.16% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.